No convincing evidence suggests that atypical antipsychotic medications are superior to typical medications for the treatment of adolescents with psychosis .
However , atypical antipsychotic medications may be more acceptable to young people because fewer symptomatic adverse effects are seen in the short term .
Little evidence is available to support the superiority of one atypical antipsychotic medication over another , but side effect profiles are different for different medications .
Treatment with olanzapine , risperidone and clozapine is often associated with weight gain .
Aripiprazole is not associated with increased prolactin or with dyslipidaemia .
Adolescents may respond better to st and ard-dose as opposed to lower-dose risperidone , but for aripiprazole and ziprasidone , lower doses may be equally effective .
BACKGROUND Schizophrenia often presents in adolescence , but current treatment guidelines are based largely on studies of adults with psychosis .
Over the past decade , the number of studies on treatment of adolescent-onset psychosis has increased .
The current systematic review collates and critiques evidence obtained on the use of various atypical antipsychotic medications for adolescents with psychosis .
OBJECTIVES To investigate the effects of atypical antipsychotic medications in adolescents with psychosis .
We review ed in separate analyses various comparisons of atypical antipsychotic medications with placebo or a typical antipsychotic medication or another atypical antipsychotic medication or the same atypical antipsychotic medication but at a lower dose .
Long-term safety, tolerability, and clinical efficacy of quetiapine in adolescents: an open-label extension trial.
Quetiapine is a novel , atypical antipsychotic agent that has been shown to provide long-term efficacy without serious adverse effects in adults . This is the first study of the extended use of quetiapine in adolescents . Five boys and 5 girls , ages 12.3 to 15.9 years , with diagnoses of schizoaffective disorder ( n = 7 ) or bipolar disorder with psychotic features ( n = 3 ) were eligible for entry into this single-site , 88-week , open-label trial . Subjects had completed a pharmacokinetic study over 23 days , during which the dosage of quetiapine was increased sequentially from 25 mg bid to a maximum of 400 mg bid ( 800 mg/day ) ( McConville et al. 2000 ) . In the open-label extension of this trial , which followed directly after this trial , a physician 's choice design allowed for flexible dose titration of quetiapine by the study physician to an optimal dose for each patient , with ending doses ranging from 300 mg/day to 800 mg/day . Concomitant medications , especially for anxiety and /or manic symptoms , were allowed as deemed necessary . Tolerability and safety were assessed using clinical laboratory tests , physical examinations , measurements of vital signs , interviews for selective symptomatology , and electrocardiograms . Psychiatric measurements included the 18-item Brief Psychiatric Rating Scale ( BPRS ) , the Clinical Global Impression ( CGI ) scale , and the modified Scale for the Assessment of Negative Symptoms ( SANS ) . Neurologic symptom ratings included the Simpson-Angus Scale and the Abnormal Involuntary Movement Scale . Mean BPRS , CGI , and SANS scores improved significantly during the trial ( p < 0.05 ) . No extrapyramidal symptoms or evidence of tardive dyskinesia was seen . Clinical ly , there was a nonsignificant increase in mean weight and body mass index at week 64 . This long-term study suggests that quetiapine is a well-tolerated antipsychotic agent that is efficacious for the treatment of symptoms of selected psychotic disorders in adolescents
No convincing evidence suggests that atypical antipsychotic medications are superior to typical medications for the treatment of adolescents with psychosis .
However , atypical antipsychotic medications may be more acceptable to young people because fewer symptomatic adverse effects are seen in the short term .
Little evidence is available to support the superiority of one atypical antipsychotic medication over another , but side effect profiles are different for different medications .
Treatment with olanzapine , risperidone and clozapine is often associated with weight gain .
Aripiprazole is not associated with increased prolactin or with dyslipidaemia .
Adolescents may respond better to st and ard-dose as opposed to lower-dose risperidone , but for aripiprazole and ziprasidone , lower doses may be equally effective .
BACKGROUND Schizophrenia often presents in adolescence , but current treatment guidelines are based largely on studies of adults with psychosis .
Over the past decade , the number of studies on treatment of adolescent-onset psychosis has increased .
The current systematic review collates and critiques evidence obtained on the use of various atypical antipsychotic medications for adolescents with psychosis .
OBJECTIVES To investigate the effects of atypical antipsychotic medications in adolescents with psychosis .
We review ed in separate analyses various comparisons of atypical antipsychotic medications with placebo or a typical antipsychotic medication or another atypical antipsychotic medication or the same atypical antipsychotic medication but at a lower dose .